Author:
Su Dan,Zhang Dadong,Chen Kaiyan,Lu Jing,Wu Junzhou,Cao Xinkai,Ying Lisha,Jin Qihuang,Ye Yizhou,Xie Zhenghua,Xiong Lei,Mao Weimin,Li Fugen
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nature reviews. Clin Oncol. 2017;14(1):57–6.
2. Riely GJ, Pao W, Combining EGFR. Targeted therapy with chemotherapy in pancreatic cancer: is timing important? Cancer Biol Ther. 2005;4(10):1096–7.
3. Stewart EL, Tan SZ, Liu G, Tsao MS. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res. 2015;4(1):67–81.
4. Diaz LA, Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32(6):579–586.
5. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–31.
Cited by
71 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献